Search

everythinglearnresearchcommunity

for

Search:↓

With a head full of hair, like a phoenix! This user has experienced positive results from using topical minoxidil and oral finasteride for 12 months, followed by 5 months of only topical use, as well as microneedling before application for 4 months. They are now considering a hair transplant in order to further enhance their results.

GT20029 showed significant hair growth and safety in phase II trials, with no adverse sexual events. Users are hopeful but concerned about future costs and systemic effects.

A user shared their 5-month progress using a topical treatment with finasteride, minoxidil, and retinoic acid, noting some hair growth but also shedding. Another user encouraged them, sharing their own experience of gradual improvement over 12 months and advising patience.

A 31-year-old Indian man shared his 6-month hair loss progress using oral finasteride and topical minoxidil, showing noticeable improvement. Replies were positive, noting thicker hair and a better hairline.

The conversation is about the timeline for Kintor's phase 3 trials for GT20029 and the potential release of the product in three years. It also mentions treatments like Minoxidil, finasteride, and RU58841.

Amplifica has not provided updates on SCUBE3 and AMP-303, raising concerns about their trial outcomes. Users also mention other treatments like Minoxidil, finasteride, RU58841, PP405, and ET-03.

The conversation is about the anticipated release date of phase II results for a hair loss treatment called GT20029 and the cautious optimism surrounding it due to past disappointments with similar treatments. Users expect an update in the next few months.

The user's hair appears to have improved, looking thicker and healthier, especially around the temples, after using topical minoxidil, finasteride, dutasteride, and tretinoin. Most participants agree the last picture shows significant improvement, though one disagrees.

Minoxidil helped with temple regrowth, and finasteride improved overall hair appearance and stopped further hair loss. Minoxidil was also applied to eyebrows and eyelids, with noticeable gains, but was stopped on the beard due to bloating.

ET-02 is seen as promising for addressing hair loss and graying, but PP405 is more advanced in development and has better publicity. Some users plan to use both treatments alongside minoxidil and dutasteride.

Pyrilutamide, a nonsteroidal antiandrogen drug under development for the potential treatment of androgenic alopecia. The conversation discusses its binding affinity to the androgen receptor and the timeline for possible availability after trials are completed in the United States and China.

A user shared their experience with microneedling and minoxidil for hair loss, avoiding finasteride due to concerns about systemic hormone effects. They reported slight hair regrowth after one month and plan to continue the regimen, noting improvements in skin sensitivity and managing dandruff with anti-dandruff shampoo.

Combining minoxidil 5%, tazarotene 0.1% cream, and lumigan for hair loss treatment is discussed. The conversation focuses on the safety and effectiveness of using these treatments together.

A 32-year-old is seeing new hair growth after two months of using minoxidil foam twice daily, finasteride every other day, and weekly microneedling. They previously had a hair transplant but did not use medication afterward, which they now regret.

A user seeks a minoxidil and tretinoin foam-based product for improving a patchy beard in India. They are unsure about the safety of alcohol-based options for beard use.

The conversation discusses the potential use of HMI 115 for hair loss and whether it could replace or be used alongside finasteride, minoxidil, and RU58841. The user is experiencing scalp inflammation and continued hair shedding despite using finasteride for 8 years.

The user reported significant hair improvement over 15 months using dutasteride, minoxidil (oral and topical), RU58841, ketoconazole, and microneedling. They are considering a hair transplant in 4-6 months.

The conversation is about finding non-alcoholic minoxidil options in India due to irritation from propylene glycol-based formulations. Suggestions include Tugain 5% foam, Morr Max 5%, minoxidil gel, and Morr F Aqua plus, with OP avoiding finasteride due to side effects.

A new topical treatment, PP405, shows promising results for hair regrowth, potentially outperforming existing treatments like finasteride and minoxidil. However, it may still need to be combined with DHT blockers for optimal results, and its long-term effectiveness remains uncertain.

KX-826 hair loss treatment completed trials with mild side effects. GT20029 may be ultimate cure, destroying androgen receptors causing baldness.

A 25-year-old switched from finasteride to dutasteride, experiencing significant hair regrowth and improved hair quality after 6 months, taking it three times a week. The user stopped finasteride entirely, citing dutasteride's longer half-life as more effective.

The user is experiencing hair regrowth using 1mg oral finasteride daily, Minoxidil foam twice a day, and microneedling weekly with a 1.5mm needle. They are seeking feedback and suggestions to optimize their hair regrowth.

A 32-year-old is seeing positive hair regrowth after nearly three months using finasteride, oral and liquid minoxidil, and microneedling, and plans to add RU58841. They are considering switching to dutasteride and possibly a hair transplant in the future.

A user is seeking advice on purchasing RU58841 with Minoxidil in Canada and is concerned about the vehicle used for the solution. They also inquire about the differences between RU58841 and topical finasteride in terms of efficacy.

The conversation discusses hair loss treatments, specifically Minoxidil, finasteride, and RU58841. It also mentions a new hair transplant therapy approved by the government.

The conversation discusses GT20029, a new topical drug for hair loss and acne without notable side effects, which has been accepted for investigational use in China. Some users express skepticism about the legitimacy of the company and the potential for other drugs like RU58841 to be developed due to patent expiration and lack of profitability.

A 28-year-old male experienced hair regrowth using a topical spray containing minoxidil, finasteride, and tretinoin, along with occasional microneedling, after stopping oral finasteride due to side effects. He is pleased with the progress after three months and plans to continue using the spray.

RU58841 showed promise for treating androgenic alopecia but research was halted due to financial and organizational changes. There were no significant safety concerns reported in human trials.

Hair loss treatments discussed include cosmeRNA, minoxidil, finasteride, RU58841, and pyrilutamide. Users debate effectiveness, side effects, and upcoming treatments, with some expressing skepticism and others optimism.

The user's 42 month experience using finasteride for hair loss, their opinion on minoxidil use and the potential of pyrilutamide and another Chinese drug as treatments.